Friulchem SpA
MIL:FCM
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IT |
|
Friulchem SpA
MIL:FCM
|
6.5m EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
960.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
230.7B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
234.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
158B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.2B USD |
Loading...
|
Market Distribution
| Min | -40 300% |
| 30th Percentile | 38.1% |
| Median | 52.1% |
| 70th Percentile | 67.8% |
| Max | 1 132% |
Other Profitability Ratios
Friulchem SpA
Glance View
Friulchem SpA engages in the research and development of pharmaceutical products for third party contract development and manufacturing organizations. The company is headquartered in Vivaro, Pordenone and currently employs 37 full-time employees. The company went IPO on 2019-07-25.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Friulchem SpA is 20.5%, which is above its 3-year median of 18.9%.
Over the last 3 years, Friulchem SpA’s Gross Margin has increased from 16.8% to 20.5%. During this period, it reached a low of 16.1% on Dec 31, 2022 and a high of 20.5% on Jul 30, 2024.